Teva Pharmaceutical Industries
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Teva Pharmaceutical Industries's revenues will wither -7.5% and EPS will contract -16.4%.
The average estimate for revenue is $5.25 billion. On the bottom line, the average EPS estimate is $1.33.
Last quarter, Teva Pharmaceutical Industries reported revenue of $4.97 billion. GAAP reported sales were 14% higher than the prior-year quarter's $4.34 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.28. GAAP EPS were -$0.09 for Q3 against $1.03 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 52.3%, 20 basis points better than the prior-year quarter. Operating margin was 21.5%, 390 basis points worse than the prior-year quarter. Net margin was -1.6%, 2,270 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $20.34 billion. The average EPS estimate is $5.36.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,470 members out of 2,540 rating the stock outperform, and 70 members rating it underperform. Among 584 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 576 give Teva Pharmaceutical Industries a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $50.28.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Teva Pharmaceutical Industries to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.
The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December
Plans to "trim the fat" have Wall Street and investors excited.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.